Liquidia Technologies Issues Response To United Therapeutics Suit Alleging Infringement Of Tyvaso Patent: Notes Statutory 30-Month Stay On Regulatory Approval Is Not Associated With Allegations Of '793 Patent, Should Have No Effect On FDA Review

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!